First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ ...

Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

Pfizer Inc. (PFE) announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI (encorafenib) in combination with ...

Bristol Myers Squibb (BMY) says its cancer drugs Opdivo and Yervoy improved progression-free survival in a Phase 3 trial for ...

Cetuximab biosimilar (CDP-1) is under development for the treatment of advanced metastatic colorectal cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma and penile ...

Dec. 23, 2024 — A research team has developed a groundbreaking technology that can treat colon cancer by converting cancer cells into a state resembling normal colon cells without killing them ...

Nivolumab plus ipilimumab prolonged PFS when compared to nivolumab alone in patients with MSI-H/dMMR unresectable or ...